Bastit et al. assessed 396 patients with non-myeloid malignancies undergoing chemotherapy and Hb < 110 g/L to receive either 200 mg of IV iron + ESAs every three weeks or ESAs every three weeks and standard practice for 16 weeks [31]. Here, GSTM1 is linked to myeloid neoplasm.